Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) was $2.07 for the day, down -2.36% from the previous closing price of $2.12. In other words, the price has decreased by -$2.36 from its previous closing price. On the day, 7.18 million shares were traded. IOVA stock price reached its highest trading level at $2.17 during the session, while it also had its lowest trading level at $2.065.
Ratios:
Our analysis of IOVA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.89 and its Current Ratio is at 3.27. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 749037504 and an Enterprise Value of 501022560. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.10 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 2.074 whereas that against EBITDA is -1.331.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.83, which has changed by -0.7754881 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is -16.51%, while the 200-Day Moving Average is calculated to be -45.11%.
Shares Statistics:
IOVA traded an average of 16.57M shares per day over the past three months and 10304300 shares per day over the past ten days. A total of 341.92M shares are outstanding, with a floating share count of 292.67M. Insiders hold about 19.12% of the company’s shares, while institutions hold 53.65% stake in the company. Shares short for IOVA as of 1756425600 were 71319978 with a Short Ratio of 4.30, compared to 1753920000 on 67706980. Therefore, it implies a Short% of Shares Outstanding of 71319978 and a Short% of Float of 21.43.
Earnings Estimates
The company has 9.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.12 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$1.0 and -$1.25 for the fiscal current year, implying an average EPS of -$1.1. EPS for the following year is -$0.66, with 10.0 analysts recommending between -$0.42 and -$0.97.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $84.2M to a low estimate of $70M. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $58.55MFor the next quarter, 11 analysts are estimating revenue of $88.56M. There is a high estimate of $106.71M for the next quarter, whereas the lowest estimate is $75.88M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $300M, while the lowest revenue estimate was $255.73M, resulting in an average revenue estimate of $275.57M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $436.22M in the next fiscal year. The high estimate is $540.4M and the low estimate is $350M.
